A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Healthy Volunteers and Patients With Chronic Hepatitis B
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2016
At a glance
- Drugs NVR 3778 (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Novira Therapeutics
- 04 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
- 04 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
- 04 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.